Braddock Martin, Murray Clare
Discovery Bioscience, AstraZeneca R&D Charnwood,Bakewell Road, Loughborough, LE11 5RH, Leicestershire, England, UK.
Expert Opin Investig Drugs. 2006 Jun;15(6):721-7. doi: 10.1517/13543784.15.6.721.
The meeting was hosted by the Strategic Research Institute (SRi) celebrating its 10th anniversary of meetings targeting the inflammatory response. Entitled the 10th International Inflammation and Immune Diseases Drug Discovery and Development World Summit, it was held in New Brunswick, USA on 20-21 March 2006. A composition of keynote sessions and two parallel tracks, the meeting drew on the wide-ranging application of targeting drugs that modulate the immune response and have anti-inflammatory activity in a number of human diseases, including psoriasis, actinic keratosis, allergic dermatitis, rheumatoid and osteoarthritis, systemic lupus erythematosus, asthma and chronic obstructive pulmonary disease. Data were presented supporting all stages of drug discovery from target identification and validation through to lead identification and optimisation to both early- and late-stage clinical development. In addition, a number of enabling technologies were described that supported the identification of potential new therapeutics, for tracking antigen-specific B- and T cells through to the development of an immune response and for the development of novel delivery vehicles as a route to minimise toxicity profiles.
本次会议由战略研究所（SRi）主办，该研究所正在庆祝其针对炎症反应的会议召开十周年。会议名为第十届国际炎症与免疫疾病药物发现与开发世界峰会，于2006年3月20日至21日在美国新不伦瑞克举行。会议由主题演讲和两条平行的分论坛组成，探讨了靶向药物在多种人类疾病中的广泛应用，这些药物可调节免疫反应并具有抗炎活性，包括银屑病、光化性角化病、过敏性皮炎、类风湿性关节炎和骨关节炎、系统性红斑狼疮、哮喘和慢性阻塞性肺疾病。会上展示的数据支持了药物发现的各个阶段，从靶点识别和验证到先导化合物的识别和优化，再到早期和晚期临床开发。此外，还介绍了一些使能技术，这些技术有助于识别潜在的新疗法，用于追踪抗原特异性B细胞和T细胞直至免疫反应的发展，以及开发新型给药载体以尽量减少毒性。
